The Drugs Controller General of India (DCGI) has given vaccine manufacturer Bharat Biotech approval for conducting Phase-III clinical trials of an intranasal booster dose for those who have received both doses of Covaxin.
Only the Central Drugs Laboratory (CDL), Kasauli, certified batches shall be used in the clinical trials, which will be conducted at nine sites, including the All India Institute of Medical Sciences, New Delhi and Bihar. The Chimpanzee Adenovirus Vectored COVID-19 Vaccine (BBV154) is to be administered through an intranasal route and each single dose is 0.5 ml.